Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

Abstract

Increased sophistication in the representation of disease dynamics in economic models is desirable when attempting to model treatment response in I-O. However, the assumptions underlying different model structures and the availability of data for health state mapping may be important limiting factors.